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Abstract: Background: Legislation preventing smoking in public places was introduced in England
in July 2007. Since then, smoke-free policies have been extended to the majority of hospitals including
those providing cancer therapies. Whilst studies have been conducted on the impact and effectiveness
of hospital smoke-free policy in the UK and other countries, there have not been any studies with a
focus on cancer care providers. Cancer patients are a priority group for smoking cessation and support
and this study aimed to examine implementation of the National Institute Clinical Excellence (NICE)
guidance (PH48) in acute cancer care trusts in the UK. Methods: Participants were recruited from UK
radiotherapy and chemotherapy departments (total 80 sites, 65 organisations) and asked to complete
a 15 min online questionnaire exploring the implementation of NICE guidance at their hospital site.
Results: Considerable variability in implementation of the NICE guidance was observed. A total
of 79.1% trusts were smoke-free in theory; however, only 18.6% were described as smoke-free in
practice. Areas of improvement were identified in information and support for patients and staff
including in Nicotine Replacement Therapy (NRT) provision, staff training and clarity on e-cigarette
policies. Conclusions: While some trusts have effective smoke-free policies and provide valuable
cessation support services for patients, improvements are required to ensure that all sites fully adopt
the NICE guidance.
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1. Introduction
Cigarette smoking remains a significant public health challenge. While rates of smoking
have continued to decline over the past decades, around 20 percent of adults in England still
smoke [1]. The smoking prevalence in the population of cancer patients rises to 31%, with 51%
being ex-smokers [2]. Smoking is a significant aetiological factor in the development of a number
of chronic illnesses including a range of cancers [3]. Cigarette smoking (both active smoking and
second-hand tobacco smoke) causes almost a fifth (19%) of all cancer cases in the UK [4], with one in
four cancer deaths attributable to cigarette smoking [5]. The Five Year Forward View [6] states that the
sustainability of the National Health Service (NHS) now requires “a radical upgrade in prevention
and public health”. The Achieving world class cancer outcomes [7] document echoes this sentiment,
advocating the importance of secondary prevention in the oncology setting. The biggest avoidable
risk factor associated with the development of a malignancy is smoking [8], consequently smoking
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cessation services play a key part. These services are both effective and cost efficient [9,10], and should
form a routine element of health care provision [11].
Legislation prohibiting smoking in the workplace and enclosed public places was introduced
in England in July 2007 as a consequence of the Health Act 2006 [12]. Since the implementation of
smoke-free legislation, many NHS secondary care settings adopted smoke-free policies for enclosed
areas and grounds [13]. This stance was further supported in 2011 by the Government Public Health
White Paper Healthy Lives, Healthy People [14], which promotes smoking cessation through secondary
care providers to reduce the burden of disease attributable to cigarette smoking. Previous studies
have shown the implementation of smoke-free policies in both acute and mental health hospital
settings is achievable [13,15] with potentially beneficial impacts on aspects such as exposure to
environmental tobacco smoke [13]. Nevertheless, there have been reported problems with the
engagement, compliance, and enforcement of smoke-free policies in hospital settings [16,17]. Therefore,
in 2013, the National Institute for Clinical Excellence (NICE) published new guidance (PH48) to support
smoking cessation, temporary abstinence from smoking, and smoke-free policies in all secondary care
settings [18].
Secondary care settings can serve as an important platform to deliver smoking cessation
advice [19]. Health care professionals such as therapeutic radiographers, allied health professionals
and nurses can be important role models to promote smoke-free norms and behaviours to support
the survivorship agenda in the oncology arena [20]. For over 10 years, NICE has recommended that
health professionals actively identify smokers and refer them to appropriate support services [21].
Evidence supports the health professional’s role as a smoking cessation practitioner, as a prompt from
a health professional is the second most common reason for a quit attempt [22]. Studies show that
between 50% and 83% of cancer patients who smoke continue to do so during their treatment and
beyond [23–25]. A recently published systematic literature review [26] highlights the significant benefit
of patients stopping or abstaining from smoking during periods of treatment such as chemotherapy
and radiotherapy. Stopping smoking, or even abstaining during treatments, can reduce acute treatment
related effects [27], improve effectiveness of treatment [28] and reduce the probability of a second
primary cancer [29] and disease recurrence [30]. Targeted cessation efforts during cancer treatments are
thus integral to reduce acute sequelae and increase the effectiveness of treatment. Therefore, the aim of
the present study is to explore UK Radiotherapy and Chemotherapy departments’ compliance with
NICE Smoking Cessation Guidance (PH48) [18].
2. Materials and Methods
2.1. Participants and Procedures
In 2015, a cross-sectional study was conducted to explore compliance with the NICE Smoking
Cessation Guidance (PH48) [18] across all UK radiotherapy and chemotherapy departments
(Total 80 sites, 65 organisations). Participants were recruited for the study using email invitations sent
to all department managers via the Society and College of Radiographer’s mailing list. The email
directed managers to the study, and targeted email invitations to forward to appropriate colleagues
with a working knowledge of the smoke-free policy within their department. This study was conducted
as an audit and the UK Research Ethics Committee deemed full ethical approval to be unnecessary.
The questionnaire was completed using a web-based survey (www.surveymonkey.com). The online
survey was designed to take no longer than 15 min to complete. Completed surveys were submitted
by each participant, and responses immediately transmitted to a secure electronic database for
subsequent analysis.
2.2. Measures
A questionnaire using both open-ended and closed-ended questions was constructed for the
purpose of this study. Using open-ended questionnaire items added richness and depth to quantitative
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data collated. Questionnaire items were developed in consultation with the research team following a
thorough review of the NICE Guidance (PH48) [18].
The draft questionnaire was piloted with five respondents internally at the author’s trust.
This allowed valuable information to be gained such as average time for completion (15 min), if the
questionnaire was fully understood and if it delivered useable data. The questionnaire was reviewed
in light of the pilot, and no significant amendments or changes were deemed necessary.
2.3. Analyses
The frequency of response for each question was determined and tabulated in Microsoft Excel.
Systematic data analysis consisted of examining the free text responses, then categorising, tabulating
and recombining the data into themes.
3. Results
3.1. Smoke-Free Policy
Of the 43 NHS hospital trusts (66% participation rate) that participated in the research study,
the majority (79.1%) were smoke-free in theory. Smoke-free in theory refers to a situation where a
smoke-free policy is in place, although it is not adhered to. However, a relatively small proportion
were described as being smoke-free in practice (18.6%), and one hospital had no imminent plans to
become smoke-free (2.3%) (Table 1). All but one oncology department in each participating hospital
currently has a smoke-free policy in place, with over half (52.4%) reporting that the policy is enforced.
Table 1. Implementation of key National Institute Clinical Excellence (NICE) Guidance.
Item Responses % (Number)
Is your hospital site smoke-free? No and currently no plans Yes in theory Yes in practice
2.3% (1) 79.1% (34) 18.6% (8)
No Yes
Is this policy enforced? 47.6% (20) 52.4% (22)
Are e-cigarettes covered in your Trust’s
smoking policy? 39.5% (15) 60.5% (23)
Is the patient’s smoking status revisited
periodically during active treatment? 68.4% (26) 31.6% (12)
Are patients informed of the potential for
increased acute side effects relating to
smoking whilst undergoing cancer therapies?
2.7% (1) 97.3% (36)
Are patients informed of the reduced
effectiveness of cancer therapies if they
smoke during treatment?
13.5% (5) 86.5% (32)
Are patients advised/encouraged to abstain
from smoking for a period of time prior to
and after a radiotherapy fraction or
administration of chemotherapy?
67.6% (25) 32.4% (12)
What training is provided to front-line staff in
smoking cessation services?
None Brief Intervention Trainng
48.1% (13) 51.9% (14)
Participants noted a number of enablers to achieving the smoke-free policy in practice, including
having designated tobacco control staff, displaying smoke-free signage and electronic messages, and
designated smoking areas, and offering smoking cessation support and disciplinary action for staff
breaches (see Table 2). Several barriers in achieving the smoke-free policy in theory were also noted
and included the lack of policy enforcement. Staff also reported concerns about the repercussions of
enforcing the policy among patients and visitors, and patients’ choice to smoke (see Table 3).
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Participants were also asked if electronic cigarettes were included in their hospital’s smoke-free
policy. Of those who responded, 60.5% reported that they were and that their use was prohibited.
Only one policy made any distinction between conventional cigarettes and electronic devices.
Operationally, two departments allowed e-cigarettes to be used within the hospital if “used discreetly”.
A further two trusts allowed e-cigarettes to be used outside, on hospital grounds. The reservation
around the use of e-cigarettes included; the fire risk related to the device and chargers; unlicensed
product with limited information admission that “policy has not caught up with e-cigarettes yet”.
Table 2. Enablers to achieve the smoke-free policy in practice.
Theme Quotes
Designated tobacco control staff and
supportive senior staff
“Designated tobacco control lead with responsibility for policy and compliance.
One full-time and four part-time advisors (charity funded). Supportive chief executive
and senior managers.”
“Dedicated staff with specialist remit to promote the anti-smoking policy.”
Smoke-free signage and electronic messages
“Large signage at all entrances to the campus and throughout the campus.
Large posters at doorways with dark red crosshatched areas to highlight non-smoking
messages. Electronic messages relayed (smoke activated) at entrance buildings asking
people to extinguish cigarettes.”
“Signage, automatic announcements at entrances and areas where smokers would
gather to announce that the site is smoke-free.”
Designated smoker areas “Three smoking shelters are provided for those who have to smoke and that is the onlyplace smoking is allowed by patients and visitors.”
Smoking cessation support
“Smoking cessation services are widely advertised.”
“Smoking cessation clinic and support on site.”
“Encouragement for anyone not to smoke, patients given patches, media involvement.“
Disciplinary action for staff breaches “Disciplinary action for staff, patrols for people moving on.”
“Policies to discipline smoking staff in uniform on site.”
Table 3. Barriers to achieving the smoke-free policy.
Theme Quotes
Policy not enforced
“Patients and visitors disregard signs and no one stops them from smoking.”
“There is an on-going tolerance/turning a blind eye to smokers standing outside
buildings on-site.”
“They (visitors) still sit on the benches outside smoking, even though they have no
smoking signs on them! Essentially you can’t enforce a non-smoking area outside.”
“It was enforced when it was first brought in.”
“In theory all staff are asked to challenge smokers. In practice this doesn't happen.”
“They started as totally smoke-free, but had to install smoking shelters away from the
main entrance, as visitors were just ignoring it anyway.”
Staff concerns about enforcing policy
“Patients and visitors can become abusive if challenged.”
“Staff cautious about challenging smokers in case of verbal abuse.”
“It was driving the smokers to find somewhere to smoke covertly which became a
greater risk.”
Policy breaches
“Ambulance/visiting health care staff smoking in uniform and undermining the policy.”
“Patients and visitors smoking outside the main entrance was a challenge for a number
of trusts. A couple of trusts erected or re-erected “smoking” shelters as a pragmatic
approach, despite it being contrary to NICE guidance—although this did not always
have the desired effect.”
“The Trust had to relent and put up a smoking shelter for (patients and visitors),
however, they rarely use it and still choose to smoke outside the main entrance.
The smoking shelter is just across the road from the main entrance!”
“Smokers disregard all enablers, it is impossible to enforce if people continue to believe
that they can smoke outside. There are very few episodes where people smoke within
the hospital but the grounds are much harder to police.”
Smoke-free signage “Not having large signage—we only have small signs and A4 posters on sandwichboards.”
Patient choice
“Patients choice . . . staff are not prepared to challenge people as they are leaving work.”
“Patients still wish to smoke . . . Freedom of individual.”
Less than a third (32.5%) reported to “always” provide written and/or verbal information and
advice about their smoke-free policy to patients (Table 4). Almost all hospitals (97.7%) reported that
Int. J. Environ. Res. Public Health 2016, 13, 1244 5 of 11
display posters and/or signage are used to convey smoke-free messages, with nearly a third (32.6%)
using staff patrol and/or recorded messages at key locations within the hospital.
Table 4. Communication of the smoke-free policy and cessation support available for patients.
Item n Never Rarely Sometimes Often Always
Patients are provided with written and/or verbal
information and advice about the smoke-free policy 40 22.5% 10.0% 17.5% 17.5% 32.5%
Information is provided about the different types of
smoking cessation pharmacotherapies and types of
behavioural support available
31 6.5% 12.9% 45.2% 19.4% 16.1%
The use of licensed nicotine-containing products for
anyone who does not want to stop smoking
completely is encouraged
28 7.1% 14.3% 50.0% 21.4% 7.1%
Licensed nicotine-containing products are offered to
all patients who smoke as appropriate 26 15.4% 19.2% 30.8% 23.1% 11.5%
People who do not want to stop smoking
completely are encouraged to use licensed
nicotine-containing products to help reduce
cravings to smoke during cancer therapies
23 13.0% 17.4% 26.1% 39.1% 4.3%
3.2. Information and Support for Patients
Participants were asked when the patient’s smoking status is investigated and whether it is
revisited periodically during active treatment. All participants who responded (n = 30) reported
that patients’ smoking status is recorded at the initial consultation phase. Of those who responded
(n = 38), less than a third (31.6%) reported that they revisit their patient’s smoking status during active
treatment. Participants were also asked if they inform patients about the acute side effects associated
with smoking whilst undergoing cancer therapies. Of those who responded (n = 37), the vast majority
(97.3%) reported that they do inform patients about the side effects of smoking during cancer treatment.
Moreover, nearly nine in ten (86.5%) stated that they warn patients about the reduced effectiveness of
cancer treatments if they continue to smoke during treatment but less than a third (32.4%) advise/or
encourage patients to abstain from smoking for a period of time prior to and after cancer treatments
(Table 1).
3.3. Provision of Smoking Cessation Support Including Pharmacotherapies
Participants were asked about the type of smoking cessation support available to patients
within their Trust. Of those who responded (n = 30), pharmacologic intervention (36.7%) was the
most frequent support available for patients, followed by individual (26.7%) and group (10.0%)
behavioural support, with some providing “other” (20.0%) support and some offering no support
(6.7%) to patients. Participants were asked whether patients are provided with information about the
different types of smoking cessation pharmacotherapies and behavioural support available (Table 4).
Pharmacotherapies are therapies employing pharmaceutical drugs, as distinguished from therapy
using radiation (radiation therapy), cytotoxic agents (chemotherapy) or movement (physical therapy).
Of those who responded (n = 31), a small proportion (16.1%) stated that they “always” provide
patients with information about the types of smoking cessation support available. Similarly, only a
small proportion (11.5%) reported that they “always” offer nicotine-containing products to patients
who smoke and/or “always” (7.1%) encourage the use of licensed nicotine-containing products for
anyone who does not want to completely quit smoking (Table 4). Smoking cessation advice was
most often provided by a nurse or Clinical Nurse Specialist (CNS), followed by medics and the
therapeutic radiographer.
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3.4. Referral Systems for Smoking Cessation Support
Participants were asked how much they agreed or disagreed with the statement “systems are
in place for recording and maintaining records of patients smoking status”, using a five-point scale
from strongly agree to strongly disagree. Of those who responded (n = 29), just over a quarter (27.6%)
agreed (including agree/strongly agree) that systems are in place to record and monitor patient
smoking status.
Participants were also asked who provides patients with the first advice regarding stopping or
reducing smoking. Of those who responded (n = 27), the majority stated that the medics (70.4%) are
the first to give patients advice about smoking cessation followed by the CNS Nurse (11.1%) and
the therapeutic radiographer (3.7), whilst others (14.8%) were unsure of who provided this advice
to patients.
3.5. Training for Staff in Smoking Cessation
Participants were asked about the type of training provided to front-line staff in smoking cessation
services. Of those who responded (n = 27), only just over half (51.9%) reported that front-line staff
receive very brief intervention advice/or advice level 1. The remainder (48.1%) received no training in
smoking cessation (Table 1).
3.6. Provision of Smoking Cessation Support for Employees
Participants were asked whether employee smoking cessation is included in their Trust’s policy
and whether cessation support is available for staff who wish to quit smoking. Of those who responded
(n = 27), the vast majority (85.2%) reported that employee smoking cessation is included in their hospital
trust’s policy, with some respondents (n = 15) reporting that their Trust provides brief intervention
support (including opportunistic advice, self-help materials, and or referral for more intensive support)
to support employee smoking cessation.
4. Discussion
This study explored compliance with the NICE Smoking Cessation Guidance (PH48) [18] in
Radiotherapy and Chemotherapy departments across the UK. Findings from this audit showed that
whilst each oncology department had a smoke-free policy, just over half (52.4%) complied with
the policy in practice. Although the majority of participants had reported to provide patients with
information about the acute side effects of smoking during cancer treatments, less than a third (32.4%)
advise patients to quit/abstain from smoking during cancer treatments. In addition, only a small
proportion of participants offer nicotine-containing products to patients who smoke during treatment.
Furthermore, respondents indicated specific concerns relating to the implementation of the smoke-free
policy in oncology departments, especially with regard to policy enforcement, safety issues, and patient
smoking norms.
It is clear from this audit that practice relating to smoking cessation support varied significantly
from policy, with just over half (52.4%) complying with their policy. Deviation from policy is unlikely
to be allowed in other areas of health care, such as standard operational procedures or infection control
policies, and should not be accepted for smoking cessation. The discord between policy and practice
reduces the overall effectiveness of any intervention. Additionally, it appears that policies do not
reflect best practice, indicated by the evidence base and information detailed in the NICE guidance.
The main areas showing deviation from policy include smoking shelters, distinction between
patients having treatment for radical or palliative intent, and facilitating non-ambulatory patients
to smoke.
It is essential that when policies are developed and reviewed that the practical application is
considered. Policies must be workable and sustainable with roles and responsibilities clearly stated.
The policy requires buy-in from the individuals and teams expected to adhere to and deliver the
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policies, and the policy must be appropriately resourced by the organisation. For many trusts, the
introduction of smoke-free policies started off positively, then later lost momentum.
Delivering smoking cessation messages needs to be done tactfully, with empathy in a
non-judgmental manner. This is perhaps especially critical when considering patients with a cancer
diagnosis. It is also important to realise that the life event of a cancer diagnosis has the potential to
be a pivotal moment in an individual’s or family’s smoking behaviour. This “teachable moment”
should not be wasted due to health professionals feeling uncomfortable or not competent to discuss
and deal with the issue. Less than a third (31.6%) revisited a patient’s smoking status during
treatment. Pattinson and Jessop [31] identified lack of knowledge or confidence as the significant barrier
rather than a previous negative experience. Almost half (48.1%) of staff had no smoking cessation
training. In this study, nurses were the main providers of smoking cessation advice and information
(56.3%), followed by therapeutic radiographers (32%). The drive for Allied Health Professional (AHP)
involvement in public health is a current priority of Public Health England (PHE) [32]. The developed
strategy [33] seeks to build the capacity, impact and profile of AHPs in public health, with a key
aim of equipping practitioners with the skills, knowledge and initiatives to promote the health and
wellbeing of individuals. A recent study highlights that AHP’s are willing to accept this role, with
over 86% of participants recognising that the prevention of ill health should be part of their role [34].
However, a separate study identified that only 35% of oncologists agreed they had the skills and
expertise to deliver smoking cessation advice [35]. This is concordant with a sample of UK therapy
radiographers, where 40% stated that they would be confident in delivering smoking cessation advice
and interventions [31]. This study identifies that practitioners have concerns regarding offending
patients and potentially compromising the therapeutic relationship. Similar practitioner perceptions
have been reported by Pattinson and Jessop [31]. It is important that professionals are effectively
trained in brief advice interventions and feel confident in using these techniques. Part of the role as a
health professional is to provide patients with the best possible health care, and negating to provide
smoking cessation advice and intervention, regardless of benevolent intention, contravenes this.
The reduced effectiveness of treatment in patients who continue to smoke, if communicated, was
mainly communicated verbally (96%). The verbal message was supported by written information
in less than a third of respondents. Given that the patient’s understanding may be compromised
by anxiety, coupled with a lot of information, it is considered good practice to provide the message
in multiple formats. Patients were informed of the increased acute side effects (97.3%) and the
reduced effectiveness of treatment (86.5%) if they continued to smoke. Less than a third (31.6%)
revisited smoking status during treatment, despite the fractionated nature of radiotherapy and
chemotherapy lending itself to such an approach. Consistent repetition of the message throughout
patients’ treatment with dialogue invited the patient to “check back” that they understand the
message—in an emphatic approach.
The section relating to pharmaceutical interventions had a significantly lower response rate
relevant to other sections. This indicates that smoking cessation services would benefit from a
multidisciplinary approach to design and delivery.
Careful consideration needs to be given to the emerging evidence for the role of e-cigarettes as
part of a harm reduction strategy. This is currently a live and controversial discussion, and a full
analysis is beyond the scope of this paper. Some headliners for consideration are provided as follows:
E-cigarettes are regulated in the UK under the Tobacco and Related Products Regulations [36],
bringing tighter standards of safety and quality, and further restrictions on advertising and promotion.
Manufacturers of e-cigarettes are required to conform to new safety standards, including specifying
the ingredients used in their product and limiting the size of tanks and refills. While e-cigarettes
are not currently available as licensed medicines, it is expected that products will come onto the
market that can be prescribed on the NHS by General Practitioners and other health care professionals
alongside other stop-smoking medicines once they are regulated as medicines [37]. Some resistance
exists from smoking cessation personnel, with over half stating they would not recommend e-cigarettes
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to clients [38]. Although this may be a moot point, as practitioner–client interactions are driven by
the client’s agenda and patients are using e-cigarettes now. Around 2.6 million adults in the UK use
e-cigarettes [39], making it the most popular smoking cessation approach in England [40]. Therefore,
clear guidance is required for practitioners.
It is essential that patients motivated to stop smoking are not inadvertently directed towards
a harm reduction approach, missing the opportunity for cessation support, as the evidence base
indicates a quit attempt as best practice [41]. Stopping smoking, abstinence, or use of NRT sit on a
spectrum, as does the use of smokeless products or vaping. The health community has previously
been cautious to engage with the tobacco industry to develop “safer” products containing nicotine or
tobacco. Reluctance and concern remains, although there is now an increasing evidence base [37,42–47]
that vaping devices are a valuable tool in a multi-facetted approach to smoking cessation and
harm reduction.
It is important to have a fully congruent message on smoke-free sites; the signage and literature
stating smoke-free trust can be undermined by the presence of cigarette butts on the floor or smoking
furniture such as ash trays on top of bins. Some may see the acceptance of e-cigarettes as a blurred
line, and this will need to be managed. Elements of the “broken window” theory [46], more commonly
employed in criminology, may apply. Trusts need to establish and maintain that the expectation, reality,
and norm is that it is a smoke-free site. This has been achieved, albeit with the considerable benefit of
law and legislation, in the aviation industry. People do not smoke on long-haul flights as they know
they cannot.
5. Limitations of Study
Questions in the survey suffered from varying amounts of non-responses. The section relating
to pharmaceutical interventions had a significantly lower response rate relevant to other sections.
This could be related to the fact that the questionnaire was sent to heads of radiotherapy departments,
who were asked to forward it to an appropriate person responsible for smoking cessation within the
trust. This indicates that smoking cessation services would benefit from a multidisciplinary approach
to design and delivery. The survey was also only sent to a targeted audience of department managers,
which may have introduced some bias if managers tried to put their departments in a more positive
light. However, the high proportion of less positive responses suggests that this was not extensive.
6. Conclusions
This audit highlights that compliance with NICE smoking cessation guidance varies significantly
between trusts. While beacons of good compliance with guidance exist, a number of trusts have
adopted a pick-and-mix approach to the guidance that has been identified in this study.
Recommendations for future implementation and compliance to the NICE guidance include:
• A greater commitment from all trusts to fully comply with the smoke-free guidance and adhere
to their policies. A key element of achieving this will be clear and consistent information and
advice to patients about the benefits of quitting smoking or abstaining from smoking during their
cancer treatment.
• A successful quit attempt or absence will be better supported by offering a full range of NRT
products beyond transdermal patches. Practitioners should have access to other delivery methods
such as quick mist sprays and inhalators that are quick acting pharmacotherapies via Patient
Group Directive or as non-medical prescribers as well as access to non-nicotine-containing
pharmaceuticals such as varenicline and bupropion.
• The creation of specific e-cigarette/vaping policies that make a distinction between conventional
cigarettes and electronic devices.
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• Practitioners and organisations have a responsibility to access free, and at the point of delivery,
smoking cessation training delivered by the National Centre for Smoking Cessation training that
includes all staff, from strategic management to non-clinical.
• A consistent electronic process and system for recording and monitoring smoking status and
making referrals. It is essential that referrals are quick and easy to make and that progress and
outcomes in each clinical area/department are monitored.
• Strong leadership and management to ensure secondary care premises (including grounds and
vehicles) remain smoke-free.
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